1526results about How to "Good antitumor activity" patented technology

An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the present invention, an antitumor agent causing reduced side effects and having a superior antitumor activity can be provided.

Relating to the medicine field, the invention specifically relates to a glycyrrhetic acid derivative with a 1, 12-diene-3-ketone skeleton or a pharmaceutically acceptable salt thereof, their preparation method and medicinal uses, in particular their application in preparing antitumor drugs. Pharmacological experiment results show that these compounds have good antitumor activity and can be used for preparing antitumor drugs clinically.

The invention relates to the technical field of bio-medicines, and particularly relates to a target delivery system based on bio-functionalized nano-silver loaded taxol or analogue thereof. The target delivery system comprises an anti-tumor medicine composition, a target ligand and a bio-degradable high-molecular polymer, wherein the anti-tumor medicine composition is prepared from nano-silver and taxol or analogue thereof. The target delivery system can selectively reach a tumor position to improve the treatment effect and reduce toxic or side effect, and can be used for effectively treating cancers.

The invention discloses a preparation method and application of a sinonovacula constricta enzymolysis polypeptide. The method is characterized by comprising the following steps: shelling sinonovacula constricta, washing, mincing, adding water in the material-liquid mass ratio of 1:(3-5) for homogenizing, and adjusting the pH value to 5.5-6.5; adding protease for performing enzymolysis at the temperature of 60-70 DEG C for 1.5-2.5 hours, wherein the adding amount of the protease is 0.2-0.3 percent based on the total mass of sinonovacula constricta; after enzymolysis, performing enzyme deactivation, and centrifuging to obtain supernatant serving as enzymatic hydrolysate; performing ultrafiltration, G-25 gel chromatography and reversed phase high-performance liquid chromatography elution on the enzymatic hydrolysate to obtain the needed sinonovacula constricta enzymolysis polypeptide. A preparation process is simple, the obtained sinonovacula constricta enzymolysis polypeptide is high in sensitivity and stability and small in side effects, plays a remarkable role in inhibiting the proliferation of DU-145 and PC-3 cells through MTT detection, and can be applied to in-vitro resistance of prostatic cancer. The preparation method plays an important role in further researching and developing functional foods and medicaments based on the sinonovacula constricta enzymolysis polypeptide and increasing the economical value of the sinonovacula constricta.

The invention relates to celastrol, a celastrol derivative, a method for preparing the celastrol derivative, biogenetic salt prepared from the celastrol derivative serving as a raw material, and application of the celastrol derivative to the preparation of an antitumor medicine. The celastrol derivative has a structure shown as a formula I, wherein R1 is H, C1-C6 straight-chain or branched-chain alkyl, benzyl and benzyl with a substituent group on a benzene ring; and R2 or R3 are independent C5-C6 cyclic hydroxyl, C1-C6 chain alkyl, phenyl and substituted phenyl respectively, or R2 and R3 are cyclized with N, and the cycle is hexahydric cyclic heterocycle containing N or O. The celastrol derivative has high antitumor activity, stability and water solubility. The celastrol derivative can be salified with one of medically acceptable inorganic acids (such as hydrochloric acid, sulfuric acid and phosphoric acid) or organic acids (citric acid, cinnamic acid, succinic acid and the like); and the salt has high water solubility.